A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

Summary

This is a phase III, randomized, observer-blind, active-controlled, parallel group, multi-center study to compare the immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 to ChAdOx1 in healthy adults aged 18 years and older

Timeline

Start

2022-10-01

Primary completion

2023-06-23

Completion

2024-02-09

Publications

• Lovell JF, Miura K, Baik YO, Lee C, Choi Y, Lee JY, Long CA, Ylade M, Lee-Llacer R, De Asis N, Trinidad-Aseron M, Manuel Ranola J, Zoleta De Jesus L, Her H. Year-Long Antibody Response to the EuCorVac-19 SARS-CoV-2 Vaccine in Healthy Filipinos. Vaccines (Basel). 2025 Jul 22;13(8):776. doi: 10.3390/vaccines13080776.
• Lovell JF, Miura K, Baik YO, Lee C, Choi Y, Her H, Lee JY, Ylade M, Lee-Llacer R, De Asis N, Trinidad-Aseron M, Ranola JM, De Jesus LZ. Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines. J Med Virol. 2024 Sep;96(9):e29927. doi: 10.1002/jmv.29927.

Drugs

Indications